Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Toripalimab and Chemotherapy for Sinonasal Cancer
NCT06940180Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2025
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Sinonasal cancer, sponsored by Dana-Farber Cancer Institute. Started Jun 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Sinonasal cancer
Beyond the preview
Go deeper on NCT06940180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940180.